I
IOOF Investment Management Limited
+ HoldingSGP
-2.21%
3M Return
$24.000
-0.698 (-2.91%)At close
Loading chart…
- High
- 24.840
- Open
- 24.740
- VWAP
- 24.26
- Volume
- 70.65K
- Mkt Cap
- —
- Low
- 23.940
- Amount
- 1.71M
- EV/EBITDA, TTM
- 0.00
SpyGlass Pharma Inc is a United States-based ophthalmic drug delivery company. The Company is focused on developing and commercializing long-term, drug delivery solutions for patients suffering from ophthalmic diseases. Its lead product candidate is SpyGlass Drug Delivery Platform with bimatoprost, which is designed to deliver three years of bimotic anti-inflammatory therapy to targeted tissues in the eye.
AI analysis of SpyGlass Pharma Inc (SGP)
SellSpyGlass Pharma, Inc. is not a good buy right now due to its significant net losses and poor technical indicators. The stock is currently priced at $24.00, with a 5-day change of -3.69% and a 20-day change of -17.47%. The RSI is at 39.059, indicating that the stock is nearing oversold territory, but the overall trend remains negative. The company reported a net loss of $19.9 million for Q2 2026, which is a substantial increase from previous losses, highlighting ongoing financial struggles. The main risk is the continued increase in expenses, particularly R&D and administrative costs, which could further impact profitability.
Valuation Metrics
The current forward P/E ratio for SpyGlass Pharma Inc (SGP) is 0.00, compared to its 5-year average forward P/E of .
Whales holding SGP
Events Timeline
News
9.508-19Yahoo FinanceStockland Reports 10.4% FFO Growth in Latest Earnings
4.508-14Yahoo FinanceCPI and PPI Data Spark Market Rally
9.508-06NASDAQ.COMSpyGlass Pharma Reports Wider Q2 Net Loss Amid Rising Expenses
9.505-15seekingalphaSpyGlass Pharma Reports Q1 Financial Results
- 8.503-26seekingalpha
SpyGlass Pharma Reports Q4 Earnings and IPO Details
SGP FAQ — answered by Alphio AI
SpyGlass Pharma Inc is a United States-based ophthalmic drug delivery company. The Company is focused on developing and commercializing long-term, drug delivery solutions for patients suffering from ophthalmic diseases. Its lead product candidate is SpyGlass Drug Delivery Platform with bimatoprost, which is designed to deliver three years of bimotic anti-inflammatory therapy to targeted tissues in the eye. It operates in the Healthcare sector.
SpyGlass Pharma, Inc. is not a good buy right now due to its significant net losses and poor technical indicators. The stock is currently priced at $24.00, with a 5-day change of -3.69% and a 20-day change of -17.47%. The RSI is at 39.059, indicating that the stock is nearing oversold territory, but the overall trend remains negative. The company reported a net loss of $19.9 million for Q2 2026, which is a substantial increase from previous losses, highlighting ongoing financial struggles. The main risk is the continued increase in expenses, particularly R&D and administrative costs, which could further impact profitability.
Community
More ↗No posts yet
Sign up or log in to join the discussionThis page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.